Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — FY2020 Earnings Presentation
23 slides from Hyphens Pharma International's earnings presentation, Mar 3, 2021
Slide 1: General Announcement: Results Briefing FY2020
3/3/2021 General Announcement::RESULTS BRIEFING FY2020 GENERAL ANNOUNCEMENT::RESULTS BRIEFING FY2020 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Title Genera
Slide 2: Hyphens Pharma International Limited Results Briefing FY2020
HYPHENS PHARMA INTERNATIONAL LIMITED Results Briefing FY2020
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: Agenda
AGENDA 1. Financial Results 2. Business Achievements 3. Business Outlook
Slide 5: Financial Results
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 6: Financial Statement
1 FINANCIAL STATEMENT FY2018 FY2019 FY2020 3Y CAGR S$'000 S$'000 S$'000 % Revenue 120,930 119,442 123,698 1.1% Cost of sales (80,125) (76,773) (79,939) -0.1% Major items in FY2020 Gross profit 40,805 42,669 43,759 3.6% Other income and gains 279 546 2,248 183.9% • Other income incl: JSS S$1.8m Distr
Slide 7: Full-Year Revenue by Segments (S$'000)
2 FULL-YEAR REVENUE BY SEGMENTS (S$’000) FY2019 FY2020 39,816 40,882 Specialty pharma 33% 33% principals Business 65,152 64,595 Proprietary 52% brands Segments 14,474 55% 18,221 Medical hypermart 12% 15% & digital 8,028 7% 7,892 57,499 60,801 6% 7,202 48% 8,374 49% Singapore 6% 7% Vietnam Geography
Slide 8: Operating Expenses
3 OPERATING EXPENSES Distribution costs: Increase primarily due to higher A&P and staff costs Admin expenses: Increase primarily due to higher R&D costs and higher provisions recorded for unutilised leave by employees Other losses: Mainly comprise allowance for inventories obsolescence COVID
Slide 9: Profit Margins
4 PROFIT MARGINS 36.0% 35.5% 35.0% 34.5% 34.0% 33.5% 33.0% 32.5% FY2018 FY2019 FY2020 GP margin 33.7% 35.7% 35.4% 9.0% 8.0% 7.0% 6.0% 5.0% 4.0% FY2018 FY2019 FY2020 EBITDA margin 6.6% 8.5% 7.5% PBT margin 5.8% 6.7% 5.7% PAT margin 4.5% 5.5% 5.0%
Slide 10: EBITDA Margin by Business Segments
5 EBITDA MARGIN BY BUSINESS SEGMENTS 14.0% 12.3% 12.0% 10.4% 9.5% 9.4% 10.0% 8.5% 7.0% 7.0% * 8.0% 5.0% 6.0% 2.8% 4.0% 2.0% 0.0% Specialty pharma principals Proprietary brands Medical hypermart & digital FY2018 FY2019 FY2020 * Exclude goodwill impairment
Slide 11: Financial Position
6 FINANCIAL POSITION S$’000 31 Dec 2020 31 Dec 2019 Total assets 87,143 80,131 Inventories 16,888 11,431 Trade & other receivables 29,421 28,654 Cash & cash equivalents 27,526 26,165 Total liabilities 39,968 36,055 Trade & other payables 33,240 30,628 Bank borrowings 2,396 300 Total equity 47,175 44
Slide 12: Cashflow Statement
7 CASHFLOW STATEMENT S$'000 FY2020 FY2019 Cashflow from operating activities Profit before tax 7,108 7,987 Adjustments for non-cash/non-op items 1,892 1,937 Changes in working capital (3,810) 935 Tax paid (1,061) (1,406) Cashflow from operating activities 4,129 9,453 Cashflow used in investing activ
Slide 13: Dividends
8 DIVIDENDS S$’000 Dividend Yield(a) Div / NP(b) FY2020 0.62 cents 2.0% 30.2% (subj to shareholders’ approval) FY2019 1 cent 3.2% 46.0% FY2018 0.55 cents 1.8% 30.5% (a) Yield is computed based on total dividends declared for the financial year divided by closing price of S$0.31 @ 2 Mar 2021. (b) Div
Slide 14: Business Achievements
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 15: Establishing a broader geographical footprint
1 • Establishing a broader geographical footprint Appointment of SUTL HK as exclusive distributor of Ocean Health® supplements in Hong Kong, Macau and Duty-Free Channels in China Appointment of Healthguard Pharmacy Limited as exclusive distributor of Ocean Health® in Sri Lanka Appointment of S
Slide 16: Investment in proprietary brands
2 • Investment in proprietary brands Patent for Ceradan® Advanced technology in UK. Patent pending in 13 other countries/ region. New product launches: + Ceradan® facelift:
Slide 17: Investment in proprietary brands: new product launches
2 • Investment in proprietary brands New product launches: NEW
Slide 18: Strengthening specialty pharma portfolio
3 • Strengthening specialty pharma portfolio New Chemical Entity (NCE) THE MUCOLYTIC OF CHOICE FOR ALL RESPIRATORY DISORDERS Chronic WHAT IS A Respiratory Tract Obstructive Other Mucus- MUCOLYTIC? Infections Pulmonary Related Disorders A: Medicine that thins the Disease (COPD) mucus, making it easie
Slide 19: Reinforcing medical hypermart and digital segment
4 • Reinforcing medical hypermart and digital segment New talents who have joined us to lead new digital initiatives. Awarded e-pharmacy licence for WellAway Pharmacy.
Slide 20: Acquisitions
5 • Acquisitions CG 210® is a globally renowned & patented topical botanical hair growth-promoting agent Hyphens has acquired the rights, titles and interests in the trademarks of CG 210® for Singapore & Malaysia New brand ownership adds to our Proprietary Brands business segment Inclusion o
Slide 21: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 22: Investing for Growth
INVESTING FOR GROWTH 1. Investment in Proprietary Brands 2. Internationalisation 3. Going Digital 4. Strengthen Specialty Pharma portfolio 5. Acquisitions 6. Challenges – COVID-19
Slide 23: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — FY2020 Earnings Presentation on 6ix